California Public Employees Retirement System Trims Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

California Public Employees Retirement System trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.5% in the 4th quarter, HoldingsChannel reports. The firm owned 629,544 shares of the medical equipment provider’s stock after selling 22,564 shares during the period. California Public Employees Retirement System’s holdings in Intuitive Surgical were worth $212,383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of the company. WCM Investment Management LLC bought a new position in shares of Intuitive Surgical during the 4th quarter valued at about $575,536,000. International Assets Investment Management LLC raised its position in shares of Intuitive Surgical by 32,360.5% during the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after buying an additional 684,749 shares in the last quarter. Alphinity Investment Management Pty Ltd raised its position in shares of Intuitive Surgical by 113.2% during the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after buying an additional 677,455 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter valued at about $178,667,000. Finally, Quadrature Capital Ltd raised its position in shares of Intuitive Surgical by 466.2% during the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after buying an additional 280,480 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

ISRG has been the topic of a number of recent analyst reports. BTIG Research increased their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday. Jefferies Financial Group raised their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday. Piper Sandler lifted their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday. StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Finally, Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a report on Friday, January 19th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Trading Up 1.4 %

Shares of NASDAQ ISRG traded up $5.27 during midday trading on Tuesday, reaching $374.20. 247,292 shares of the stock were exchanged, compared to its average volume of 1,656,004. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The stock has a 50 day moving average price of $386.57 and a 200-day moving average price of $344.41. The company has a market capitalization of $132.64 billion, a P/E ratio of 66.59, a P/E/G ratio of 5.69 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the previous year, the firm earned $1.00 earnings per share. Intuitive Surgical’s revenue was up 11.5% compared to the same quarter last year. On average, analysts forecast that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In related news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Fredrik Widman sold 5,041 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the transaction, the vice president now owns 110 shares in the company, valued at $43,677.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. Over the last three months, insiders have sold 248,418 shares of company stock valued at $95,927,097. Corporate insiders own 0.80% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.